论文部分内容阅读
目的探讨通心络胶囊治疗冠心病心绞痛伴高同型半胱氨酸血症患者的治疗效果。方法抽取2014年2月至2015年10月符合选取标准的62例冠心病心绞痛伴高同型半胱氨酸血症患者,随机分为研究组和常规组,每组31例。常规组采用阿司匹林等药物进行常规治疗,研究组在常规组治疗基础上加用通心络胶囊。对比两组患者临床疗效及治疗前后同型半胱氨酸和血脂水平变化情况。结果研究组治疗总有效率为90.32%,常规组为67.74%,组间比较差异有统计学意义(P<0.05)。治疗前研究组同型半胱氨酸水平及血脂各指标与常规组比较差异未见统计学意义(P>0.05);治疗后,研究组同型半胱氨酸水平及血脂各指标显著优于常规组,差异有统计学意义(P<0.05)。结论对冠心病心绞痛伴高同型半胱氨酸血症患者采用通心络胶囊治疗可显著提高治疗效果,改善同型半胱氨酸及血脂水平,具有一定临床价值,值得推广运用。
Objective To investigate the therapeutic effect of Tongxinluo capsule in treating patients with coronary heart disease with hyperhomocysteinemia. Methods Totally 62 patients with coronary heart disease with hyperhomocysteinemia who met the selection criteria from February 2014 to October 2015 were randomly divided into study group and conventional group, with 31 cases in each group. The conventional group was treated with aspirin and other drugs routinely, and the study group was given Tongxinluo capsule on the basis of conventional treatment. The clinical efficacy of the two groups were compared before and after treatment with homocysteine and blood lipid levels. Results The total effective rate was 90.32% in the study group and 67.74% in the conventional group. There was significant difference between the two groups (P <0.05). Before treatment, homocysteine levels and serum lipids were not significantly different between the two groups (P> 0.05). After treatment, the levels of homocysteine and lipid in the study group were significantly better than those in the conventional group , The difference was statistically significant (P <0.05). Conclusion The treatment of Tongxinluo Capsule in patients with coronary heart disease angina with hyperhomocysteinemia can significantly improve the therapeutic effect, improve homocysteine and blood lipid levels, which has certain clinical value and is worth popularizing and applying.